The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...
On December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron Pharmaceuticals, Inc.
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
In March 2025, Japan’s Ministry of Health, Labour and Welfare has approved the marketing and manufacturing of Dupixent ...
Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...
Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...
Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44 th annual JP Morgan Healthcare Conference in San ...
Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as it seeks to expand a vaccines business currently ...
The deal gives Sanofi access to Dynavax’s approved hepatitis B vaccine, News.Az reports, citing Reuters. This acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback